03.19.25 -- Comparison Of Sterilization Methods: Vaporized Vs. Aerosolized Hydrogen Peroxide

Explore our innovative approach to establishing leak rate acceptance criteria and ensure the integrity of your freeze-drying processes for sterile pharmaceutical production.

High concentration formulations often present challenges with regard to viscosity as well as potential changes in the behavior upon stability. Discover solutions to mitigate high viscosity.

Reduce the cost and complexity of viral clearance validation with non-infectious surrogates. Learn how CHO-RVLP and MVM-MVP enable safer, more efficient biopharmaceutical process development.

For bispecific antibodies (bsAbs), the goal of downstream process development is to develop a method for obtaining highly purified bsAbs with optimal recovery and quality.

In this exclusive interview, Dr. Quentin Bazot, Head of Innovation and Development from ABL, shares insights into the impact that a new photometer is having on ABL's AAV process development workflow.

Determining size homogeneity of a mAb in solution is important for comparability. Explore how an IgG1 antibody was cleaved into antigen-binding fragments using pepsin and papain digestion.

Sterile fill finish operations can be complex. Those on the floor handling these products every day answer the question, "What are the top things customers should consider when beginning this step?"

While most hcDNA molecules outside AAV particles can be eliminated during downstream processing, encapsidated hcDNA molecules remain largely undetectable. Learn how to overcome this critical issue.